Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MALTOMA
MCID: LYM129
MIFTS: 64

Lymphoma, Mucosa-Associated Lymphoid Type (MALTOMA)

Categories: Blood diseases, Cancer diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Lymphoma, Mucosa-Associated Lymphoid Type

About this section

MalaCards integrated aliases for Lymphoma, Mucosa-Associated Lymphoid Type:

Name: Lymphoma, Mucosa-Associated Lymphoid Type 56 73 37
Malt Lymphoma 56 12 58 73 54 15 17
Mucosa-Associated Lymphoid Tissue Lymphoma 12 58 71
Gastric Lymphoma, Primary 56 73 54
Lymphoma, Malt, Somatic 56 73 13
Extranodal Marginal Zone B-Cell Lymphoma 58 71
Marginal Zone B-Cell Lymphoma 73 71
Maltoma 58 73
Mucosa-Associated Lymphatic Tissue Lymphoma 58
Familial Primary Gastric Lymphoma 71
Lymphoma, B-Cell, Marginal Zone 43
Lymphoma, Gastric, Primary 39
Primary Gastric Lymphoma 73
Gastric Lymphoma 71

Characteristics:

Orphanet epidemiological data:

58
malt lymphoma
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/100000 (United States),1-9/100000 (Europe); Age of onset: Adult; Age of death: normal life expectancy;

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases
Anatomical: Blood diseases Gastrointestinal diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 33
Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:0050909
OMIM 56 137245
MeSH 43 D018442
ICD10 via Orphanet 33 C88.4
UMLS via Orphanet 72 C0242647
Orphanet 58 ORPHA52417
MedGen 41 C1850900
UMLS 71 C0242647 C0349532 C1367654 more
Sources

Summaries for Lymphoma, Mucosa-Associated Lymphoid Type

About this section
UniProtKB/Swiss-Prot : 73 Lymphoma, mucosa-associated lymphoid type: A subtype of non-Hodgkin lymphoma, originating in mucosa-associated lymphoid tissue. MALT lymphomas occur most commonly in the gastro- intestinal tract but have been described in a variety of extranodal sites including the ocular adnexa, salivary gland, thyroid, lung, thymus, and breast. Histologically, they are characterized by an infiltrate of small to medium-sized lymphocytes with abundant cytoplasm and irregularly shaped nuclei. Scattered transformed blasts (large cells) also are present. Non-malignant reactive follicles are observed frequently. A pivotal feature is the presence of lymphoepithelial lesions, with invasion and partial destruction of mucosal glands and crypts by aggregates of tumor cells.

MalaCards based summary : Lymphoma, Mucosa-Associated Lymphoid Type, also known as malt lymphoma, is related to follicular lymphoma and lymphoma. An important gene associated with Lymphoma, Mucosa-Associated Lymphoid Type is BCL10 (BCL10 Immune Signaling Adaptor), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Clarithromycin and Omeprazole have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone and t cells, and related phenotypes are nausea and vomiting and hyperhidrosis

Disease Ontology : 12 A marginal zone B-cell lymphoma that has material basis in mucosal tissue involved in antibody production.

OMIM : 56 The concept of mucosa-associated lymphoid tissue (MALT) lymphomas was introduced by Isaacson and Wright (1983). MALT lymphomas are now recognized as a distinct subtype of non-Hodgkin lymphoma (605027). B-cell lymphomas of mucosa-associated lymphoid tissue (MALT lymphomas) are the most common form of lymphoma arising in extranodal sites, in most cases arising in the gastric mucosa (Isaacson and Spencer, 1995). (137245)

Sources

Related Diseases for Lymphoma, Mucosa-Associated Lymphoid Type

About this section

Diseases related to Lymphoma, Mucosa-Associated Lymphoid Type via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 560)
# Related Disease Score Top Affiliating Genes
1 follicular lymphoma 33.4 IRF4 IGH CXCR5 CD5 CD40 CCND1
2 lymphoma 32.4 MALT1 IRF4 CXCR5 CXCL13 CD5 CD40
3 nodal marginal zone lymphoma 32.2 MALT1 IGH CD5 BCL6
4 gastric lymphoma 32.1 S100A8 MALT1 IRF4 CXCR5 CXCL13 BCL6
5 b-cell lymphoma 32.0 MALT1 IRF4 IGH FOXP1 CXCR5 CXCL13
6 marginal zone b-cell lymphoma 31.9 S100A8 MALT1 KDM4C IRF4 FOXP1 CD5
7 lymphoma, hodgkin, classic 31.8 KDM4C IRF4 CD40 CCR6 BCL6
8 diffuse large b-cell lymphoma 31.8 MALT1 IRF4 FOXP1 CD5 CD40 CCND1
9 lung lymphoma 31.7 MALT1 IRF4 CD5 BCL6
10 bladder lymphoma 31.6 CD5 BCL6
11 plasmacytoma 31.4 IRF4 IGH CD5 CCND1
12 breast lymphoma 31.4 IRF4 CD5 BCL6
13 lymphoma, non-hodgkin, familial 31.3 MALT1 KDM4C IRF4 IGH CXCR5 CD5
14 orbit lymphoma 31.3 MALT1 FOXP1 BCL10
15 gallbladder lymphoma 31.3 MALT1 CD5 BIRC3
16 gastrointestinal lymphoma 31.3 MALT1 CD5 CCND1 BIRC3 BCL6
17 prostate lymphoma 31.3 CD5 BCL6
18 splenic marginal zone lymphoma 31.3 MALT1 FOXP1 CD5 CD40 BIRC3 BCL6
19 nodal marginal zone b-cell lymphoma 31.2 MALT1 BCL6
20 mantle cell lymphoma 31.2 MALT1 IGH CD5 CD40 CCND1 BCL6
21 autoimmune lymphoproliferative syndrome, type v 31.2 IGH CD5 BCL6
22 peripheral t-cell lymphoma 31.2 CXCL13 CD5 CCND1 BCL6
23 burkitt lymphoma 31.2 IRF4 CXCR5 CXCL13 CD40 CCND1 CARD11
24 plasma cell neoplasm 31.1 IRF4 CD5 CCND1 BCL6
25 primary mediastinal large b-cell lymphoma 31.1 IRF4 BCL6
26 primary cutaneous marginal zone b-cell lymphoma 31.1 MALT1 IRF4 BCL10
27 alpha chain disease 31.1 MALT1 FOXP1 CD5 CCND1 BIRC3 BCL10
28 t-cell adult acute lymphocytic leukemia 31.1 IRF4 CD5 CCR6 CARD11
29 combined t cell and b cell immunodeficiency 31.0 IRF4 CD40 CCR6
30 intravascular large b-cell lymphoma 31.0 CD5 BCL6
31 lymphoplasmacytic lymphoma 30.9 KDM4C IRF4 IGH CD5 CD40 CCND1
32 gastrointestinal system disease 30.9 S100A8 MADCAM1 KDM4C CCR6
33 systemic lupus erythematosus 30.9 S100A8 IRF4 CXCR5 CXCL13 CD5 CD40
34 acquired immunodeficiency syndrome 30.9 MADCAM1 CXCR5 CCR6 CCND1 BCL6
35 mature b-cell neoplasm 30.9 KDM4C IRF4 CD5 CD40 CCR6 CCND1
36 myeloma, multiple 30.8 KDM4C IRF4 CD5 CD40 CCR6 CCND1
37 primary central nervous system lymphoma 30.8 CXCR5 CXCL13 BCL6
38 colon lymphoma 30.8 CD5 BCL6
39 follicular lymphoma 1 30.8 IGH BCL6 BCL10
40 leukemia, acute lymphoblastic 3 30.8 IGH FOXP1 CXCR5 CXCL13
41 plasma cell leukemia 30.7 IRF4 CCND1
42 adult lymphoma 30.7 IRF4 CD5 BCL6
43 central nervous system lymphoma 30.7 MALT1 FOXP1 CXCR5 CXCL13 BCL6
44 cll/sll 30.7 KDM4C CD5 CCR6 CCND1 BCL6
45 lymphosarcoma 30.7 IGH BCL6
46 immune deficiency disease 30.6 IRF4 CD5 CD40 CCR6 BCL6
47 composite lymphoma 30.6 CD5 BCL6
48 leukemia, chronic lymphocytic 30.5 KDM4C IRF4 IGH DUSP5 CXCR5 CD5
49 extramedullary plasmacytoma 30.3 IRF4 CCND1
50 inflammatory bowel disease 30.2 TLR1 S100A8 MADCAM1 CD40 CCR6 CCND1

Graphical network of the top 20 diseases related to Lymphoma, Mucosa-Associated Lymphoid Type:



Diseases related to Lymphoma, Mucosa-Associated Lymphoid Type
Sources

Symptoms & Phenotypes for Lymphoma, Mucosa-Associated Lymphoid Type

About this section

Human phenotypes related to Lymphoma, Mucosa-Associated Lymphoid Type:

58 31 (show all 19)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 nausea and vomiting 58 31 hallmark (90%) Very frequent (99-80%) HP:0002017
2 hyperhidrosis 58 31 hallmark (90%) Very frequent (99-80%) HP:0000975
3 fatigue 58 31 hallmark (90%) Very frequent (99-80%) HP:0012378
4 fever 58 31 hallmark (90%) Very frequent (99-80%) HP:0001945
5 anemia 58 31 hallmark (90%) Very frequent (99-80%) HP:0001903
6 weight loss 58 31 hallmark (90%) Very frequent (99-80%) HP:0001824
7 pulmonary infiltrates 58 31 hallmark (90%) Very frequent (99-80%) HP:0002113
8 b-cell lymphoma 58 31 hallmark (90%) Very frequent (99-80%) HP:0012191
9 constipation 58 31 frequent (33%) Frequent (79-30%) HP:0002019
10 recurrent respiratory infections 58 31 occasional (7.5%) Occasional (29-5%) HP:0002205
11 visual impairment 58 31 occasional (7.5%) Occasional (29-5%) HP:0000505
12 abdominal pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0002027
13 mediastinal lymphadenopathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0100721
14 abnormality of the thyroid gland 58 31 occasional (7.5%) Occasional (29-5%) HP:0000820
15 posterior uveitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0012123
16 abnormal nasolacrimal system morphology 31 occasional (7.5%) HP:0000614
17 lymphadenopathy 58 Occasional (29-5%)
18 abnormality of the nasolacrimal system 58 Occasional (29-5%)
19 gastric lymphoma 31 HP:0045038

Clinical features from OMIM:

137245

GenomeRNAi Phenotypes related to Lymphoma, Mucosa-Associated Lymphoid Type according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.4 BCL10 BIRC3 CARD11 DUSP5 MALT1
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.4 BCL10 BIRC3 CARD11 CCND1 CD40 DUSP5

MGI Mouse Phenotypes related to Lymphoma, Mucosa-Associated Lymphoid Type:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.86 BCL10 BCL6 BIRC3 CARD11 CCND1 CCR6
2 immune system MP:0005387 9.53 BCL10 BCL6 BIRC3 CARD11 CCND1 CCR6
Sources

Drugs & Therapeutics for Lymphoma, Mucosa-Associated Lymphoid Type

About this section

Drugs for Lymphoma, Mucosa-Associated Lymphoid Type (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 398)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clarithromycin Approved Phase 4 81103-11-9 84029
2
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
3
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
4
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
5
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
6
Potassium citrate Approved, Investigational, Vet_approved Phase 4
7
Nitazoxanide Approved, Investigational, Vet_approved Phase 4 55981-09-4 41684
8
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
9
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
10
Ofloxacin Approved Phase 4 82419-36-1 4583
11 Cytochrome P-450 CYP3A Inhibitors Phase 4
12 Respiratory System Agents Phase 4
13 Expectorants Phase 4
14 Antiparasitic Agents Phase 4
15 Antiprotozoal Agents Phase 4
16 Antimalarials Phase 4
17 Antibiotics, Antitubercular Phase 4
18 Cytochrome P-450 Enzyme Inhibitors Phase 4
19 Topoisomerase Inhibitors Phase 4
20 Pharmaceutical Solutions Phase 4
21 Renal Agents Phase 4
22 Anti-Infective Agents, Urinary Phase 4
23 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
24
Pixantrone Approved, Investigational Phase 3 144510-96-3
25
Idarubicin Approved Phase 3 58957-92-9 42890
26 Orange Approved Phase 3
27
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
28
Tinidazole Approved, Investigational Phase 3 19387-91-8 5479
29
Chlorambucil Approved Phase 3 305-03-3 2708
30
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
31
Lenograstim Approved, Investigational Phase 3 135968-09-1
32
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
33
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
34
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
35
Acyclovir Approved Phase 3 59277-89-3 2022
36
Ribavirin Approved Phase 3 36791-04-5 37542
37
Palivizumab Approved, Investigational Phase 3 188039-54-5
38
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
39
Dalteparin Approved Phase 3 9005-49-6
40
Captopril Approved Phase 3 62571-86-2 44093
41
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
42
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
43
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
44
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 468682 2826718
45
Piperacillin Approved Phase 3 66258-76-2 43672
46
Tazobactam Approved Phase 3 89786-04-9 123630
47
Vancomycin Approved Phase 3 1404-90-6 441141 14969
48
Darbepoetin alfa Approved, Investigational Phase 3 209810-58-2, 11096-26-7
49
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
50
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478

Interventional clinical trials:

(show top 50) (show all 654)
# Name Status NCT ID Phase Drugs
1 Helicobacter Pylori Eradication Rates of Concomitant Therapy and Tailored Therapy Based on 23S Ribosomal RNA Point Mutations Associated With Clarithromycin Resistance: A Multicenter Prospective Randomized Study Unknown status NCT03130452 Phase 4 Lansoprazole 30mg;Amoxicillin 1.0g Tab;Clarithromycin 500mg;Metronidazole 500 mg
2 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
3 Comparison of Dexlansoprazole-based Triple and Rabeprazole-based Triple Therapies for Helicobacter Pylori Infection Completed NCT02541786 Phase 4 dexlansoprazole based triple therapy;rabeprazole-based triple therapy
4 Prospective, Randomized Controlled Trial Comparing High Dose Amoxicillin Versus Tetracycline Based Quadruple Therapy as Second-line Treatment for Resistant Helicobacter Pylori Infection Completed NCT02175927 Phase 4 Lansoprazole;Bismuth Potassium Citrate;Metronidazole;Amoxicillin;Tetracycline
5 A Randomized Trial of Standard vs Half Dose Rabeprazole, Clarithromycin, Metronidazole and Amoxicillin in the Treatment of Helicobacter Pylori Infection Completed NCT01219764 Phase 4 Rabeprazole, metronidazole, Clarithromycin, Amoxicillin
6 A Greek, Single Center, Randomized, Double Blind Controlled Clinical Study Comparing the 10-day Versus the 14-day Concomitant Proton Pump Inhibitor [PPI] + Amoxicillin + Metronidazole + Clarithromycin (PAMC) Therapeutic Scheme as First-line Treatment Strategy for the Eradication of H. Pylori Infection Completed NCT02959255 Phase 4 Esomeprazole
7 Comparison Between Hybrid, Reverse Hybrid, and Non-Bismuth Levofloxacin Quadruple Regimens for Helicobacter Pylori Infection in Egypt: A Randomized Controlled Trial Completed NCT04039412 Phase 4 Hybrid regimen;Reverse hybrid regimen;Levofloxacin quadruple regimen
8 Intraluminal Therapy for Helicobacter Pylori Infection Completed NCT03124420 Phase 4 Lansoprazole;Amoxicillin;Clarithromycin
9 Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan Completed NCT03524833 Phase 4 Metronidazole;Lansoprazole, Amoxicillin, Metronidazole
10 Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan Completed NCT03521726 Phase 4 Amoxicillin;Rabeprazole, Amoxicillin
11 Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan Completed NCT03516669 Phase 4 Clarithromycin;Amoxicillin, Clarithromycin
12 High Dose Dual Therapy (HDDT) for Eradication of Helicobacter Pylori Infection Recruiting NCT02553083 Phase 4 Nexium 40 mg;amoxicillin 1.5 gr;doxycycline 200 mg;Nexium 20 mg;clarythromicin 500 mg;amoxicillin 1gr
13 Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan Not yet recruiting NCT03832465 Phase 4 Levofloxacin film-coated tablet;Levofloxacin intravenous solution
14 AN OPEN-LABEL TRIAL OF REDUCED- DOSE PYLERA (BISMUTH, METRONIDAZOLE, TETRACYCLINE), AMOXICILLIN, AND ESOMEPRAZOLE IN THE TREATMENT OF HELICOBACTER PYLORI INFECTION Withdrawn NCT02045251 Phase 4 Pylera based reduced regimen
15 Treatment of Low-Grade Gastric Non-Hodgkin‘s Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT) Type Stages IE & II1E (HELYX-Study) Unknown status NCT00154440 Phase 3 proton pump inhibitor;clarithromycin;amoxicillin;metronidazole
16 A European Randomized Multicenter Study of Interferon Alfa-2b Versus No Treatment After Intensive Therapy and Autologous Hematopoietic Stem Cell Transplantation for Relapsing Lymphoma Patients (Non-Hodgkin Lymphomas and Hodgkin's Disease) Unknown status NCT00003924 Phase 3
17 A Randomized Phase III Trial Comparing the Combination of Fludarabine, BBR 2778 (Pixantrone) and Rituximab (FP-R) With the Combination of Fludarabine and Rituximab (F-R) in the Treatment of Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Unknown status NCT00551239 Phase 3 fludarabine phosphate;pixantrone dimaleate
18 Randomised Controlled Trial of CID (Chlorambucil, Idarubicin, Dexamethasone) Versus CD (Chlorambucil, Dexamethasone) for Induction of Remission in Low Grade Non-Hodgkin's Lymphoma (Kiel Classification) Followed by Randomised Controlled Assessment of Standard Dose Interferon Versus Low Dose Interferon Versus No Further Therapy as Maintenance Treatment After Remission Induction Unknown status NCT00003639 Phase 3 chlorambucil;dexamethasone;idarubicin
19 Randomized Controlled Study of Iron Supplementation to Support the Response to Recombinant Human Erythropoietin for the Treatment of Chemotherapy-Induced Anaemia Unknown status NCT00482716 Phase 3
20 Randomised Study Comparing 6 And 8 Cycles Of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine And Prednisone) At 14-Day Intervals (CHOP-14), Both With Or Without The Monoclonal Anti-CD20 Antibody Rituximab In Patients Aged 61 To 80 Years With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
21 The Utility of LymphoScan Imaging in the Dectection of Residual Tumor After Chemotherapy and/or Radiotherapy in Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
22 The Utility of LymphoScan Imaging in the Localization and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
23 A Randomized Phase III Study to Assess Intensification of the Conditioning Regimen for Allogenic Stem Cell Transplantation (ALLO-SCT) for Leukemia or Myelodysplastic Syndrome With a High Risk of Relapse Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
24 A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE] Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
25 Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Levofloxacin With That of Cefepime in the Treatment of Fever and Neutropenia - Phase IIIB Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
26 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
27 Protocol for a Randomised Trial of Observation Versus Chlorambucil After Anti-Helicobacter Therapy in Low Grade Gastric Lymphoma Unknown status NCT00003617 Phase 3 chlorambucil;clarithromycin;omeprazole;tinidazole
28 Multicenter Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in Extranodal Marginal Zone B-cell Lymphoma of Mucosa Associated Lymphoid Tissue (MALT Lymphoma) Completed NCT00210353 Phase 3 chlorambucil (drug);rituximab+chlorambucil;rituximab
29 Randomized Trial of Autologous GVHD for Refractory Lymphoma Completed NCT00003414 Phase 3 busulfan;cyclophosphamide;cyclosporine
30 A Double-Blind Study Of Nutritional Intervention For The Treatment Of Cancer Cachexia Using Juven® Nutritional Supplement Completed NCT00053053 Phase 3
31 A Phase III Randomized Trial of CHOP Chemotherapy Plus Rituxan (IDEC-C2B8) Versus CHOP Chemotherapy Alone for Newly Diagnosed, Previously Untreated, Aggressive Non-Hodgkin's Lymphoma Completed NCT00004112 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
32 A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies Completed NCT00438958 Phase 3
33 Phase III Trial of T Lymphocyte Depletion by Elutriation and CD34 Add-Back for Allogeneic Bone Marrow Transplantation Completed NCT00265837 Phase 3
34 Randomized Placebo Controlled Double Blind Study of Restasis Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
35 A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
36 A Randomized Double-Blind Placebo-Controlled Phase III Study To Evaluate The Safety And Efficacy Of Palivizumab Combined With Aerosolized Ribavirin Compared To Ribavirin Alone To Treat RSV Pneumonia In Patients With Bone Marrow Transplants (BMT) Completed NCT00014391 Phase 3 ribavirin
37 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
38 A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters Completed NCT00006083 Phase 3 Fragmin
39 A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors Completed NCT00005590 Phase 3 levofloxacin
40 Phase III Study of Captopril in Patients Undergoing Autologous Bone Marrow/Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
41 A Randomized, Comparative Study of Itraconazole Versus Fluconazole for Prevention of Aspergillus Infections in Peripheral Blood Stem Cell and Marrow Transplant Recipients Completed NCT00003883 Phase 3 fluconazole;itraconazole
42 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Completed NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
43 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
44 The Effects of Procrit (Epoetin Alfa) on Hemoglobin Symptom Distress and Quality of Life During Chemotherapy in Lymphoma Patients With Mild to Moderate Anemia A Multicenter Trial Completed NCT00003341 Phase 3
45 Music Video and Adolescent/Young Adult Resilience During Transplant Completed NCT00305851 Phase 3
46 Does Hypericum Reduce Fatigue in Cancer Patients on Chemotherapy? A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT00005805 Phase 3
47 Vancomycin Versus Placebo in Persistently Febrile Granulocytopenic Patients Given Piperacillin/Tazobactam Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
48 A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
49 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
50 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B

Search NIH Clinical Center for Lymphoma, Mucosa-Associated Lymphoid Type

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Lymphoma, Mucosa-Associated Lymphoid Type cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Lymphoma, Mucosa-Associated Lymphoid Type:
Hematopoietic stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Lymphoma, Mucosa-Associated Lymphoid Type:
Bone marrow-derived hematopoietic stem cells

Cochrane evidence based reviews: lymphoma, b-cell, marginal zone

Sources

Genetic Tests for Lymphoma, Mucosa-Associated Lymphoid Type

About this section
Sources

Anatomical Context for Lymphoma, Mucosa-Associated Lymphoid Type

About this section

MalaCards organs/tissues related to Lymphoma, Mucosa-Associated Lymphoid Type:

40
B Cells, Bone, T Cells, Thyroid, Bone Marrow, Lung, Breast
Sources

Publications for Lymphoma, Mucosa-Associated Lymphoid Type

About this section

Articles related to Lymphoma, Mucosa-Associated Lymphoid Type:

(show top 50) (show all 3024)
# Title Authors PMID Year
1
Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. 54 61 56
9989495 1999
2
The biology of low grade MALT lymphoma. 61 56
7629280 1995
3
Familial primary gastric lymphoma. 56
8432445 1993
4
Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma. 56
6193858 1983
5
Regression of rectal mucosa-associated lymphoid tissue (MALT) lymphoma after antibiotic treatments. 54 61
20518898 2010
6
The t(14;18)(q32;q21)/IGH-MALT1 translocation in MALT lymphomas contains templated nucleotide insertions and a major breakpoint region similar to follicular and mantle cell lymphoma. 54 61
19965626 2010
7
Prevalence of Helicobacter pylori vacA, cagA, iceA and oipA genotypes in Tunisian patients. 54 61
20302630 2010
8
Primary central nervous system mucosa-associated lymphoid tissue lymphoma: case report and literature review. 54 61
19525185 2009
9
Antibodies to Helicobacter pylori and CagA protein are associated with the response to antibacterial therapy in patients with H. pylori-positive API2-MALT1-negative gastric MALT lymphoma. 54 61
19385974 2009
10
Auto-ubiquitination-induced degradation of MALT1-API2 prevents BCL10 destabilization in t(11;18)(q21;q21)-positive MALT lymphoma. 54 61
19279678 2009
11
[Primary ocular adnexal lymphoproliferative lesions: clinicopathologic features and genetic alterations]. 54 61
19159526 2008
12
BCL10 nuclear expression and t(11;18)(q21;q21) indicate nonresponsiveness to Helicobacter pylori eradication of Chinese primary gastric MALT lymphoma. 54 61
18949449 2008
13
Association of polymorphisms of NOD2, TLR4 and CD14 genes with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma. 54 61
19189651 2008
14
Overexpression of B cell-activating factor of TNF family (BAFF) is associated with Helicobacter pylori-independent growth of gastric diffuse large B-cell lymphoma with histologic evidence of MALT lymphoma. 54 61
18628489 2008
15
Influence of Helicobacter pylori infection persistence on bcl-2 expression in gastric mucosa inflammatory cells. 54 61
19175059 2008
16
[Frequency of genetic aberrations in mucosa-associated lymphoid tissue lymphoma of different sites]. 54 61
19094584 2008
17
Significance of CXCR3 expression in gastric low-grade B-cell lymphoma of mucosa-associated lymphoid tissue type for predicting responsiveness to Helicobacter pylori eradication. 54 61
18616679 2008
18
Distinct signatures of B-cell homeostatic and activation-dependent chemokine receptors in the development and progression of extragastric MALT lymphomas. 54 61
18561120 2008
19
Translocations involving the immunoglobulin heavy chain gene locus predict better survival in gastric diffuse large B-cell lymphoma. 54 61
18445693 2008
20
Chromosomal instability in gastric mucosa-associated lymphoid tissue lymphomas: a fluorescent in situ hybridization study using a tissue microarray approach. 54 61
18234275 2008
21
CXCL13, CCL21, and CXCL12 expression in salivary glands of patients with Sjogren's syndrome and MALT lymphoma: association with reactive and malignant areas of lymphoid organization. 54 61
18354239 2008
22
Chromosomal translocations involving BCL6 in MALT lymphoma. 54 61
18166802 2008
23
[Abnormal expression of bcl-10 protein in extranodal marginal zone B cell lymphoma of mucosa-associated lymphoid tissue lymphoma type]. 54 61
18346354 2007
24
Generation of a new monoclonal antibody against MALT1 by genetic immunization. 54 61
17451356 2007
25
CD5-positive mucosa-associated lymphoid tissue (MALT) lymphoma of ocular adnexal origin: usefulness of fluorescence in situ hybridization for distinction between mantle cell lymphoma and MALT lymphoma. 54 61
17300675 2007
26
Differential response to H. pylori eradication therapy of co-existing diffuse large B-cell lymphoma and MALT lymphoma of stomach-significance of tumour cell clonality and BCL10 expression. 54 61
17167822 2007
27
Cytogenetic abnormalities in MALT lymphomas and their precursor lesions from different organs. A fluorescence in situ hybridization (FISH) study. 54 61
17222250 2007
28
MALT1, BCL10 and FOXP1 in salivary gland mucosa-associated lymphoid tissue lymphomas. 54 61
17199743 2007
29
The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North America. 54 61
17122510 2006
30
Deviated VH4 immunoglobulin gene usage is found among thyroid mucosa-associated lymphoid tissue lymphomas, similar to the usage at other sites, but is not found in thyroid diffuse large B-cell lymphomas. 54 61
16980947 2006
31
MALT1 gene rearrangements and NF-kappaB activation involving p65 and p50 are absent or rare in primary MALT lymphomas of the breast. 54 61
16917511 2006
32
High BCL6 expression predicts better prognosis, independent of BCL6 translocation status, translocation partner, or BCL6-deregulating mutations, in gastric lymphoma. 54 61
16772602 2006
33
Molecular pathogenesis of MALT lymphoma: two signaling pathways underlying the antiapoptotic effect of API2-MALT1 fusion protein. 54 61
16572204 2006
34
Distinct comparative genomic hybridisation profiles in gastric mucosa-associated lymphoid tissue lymphomas with and without t(11;18)(q21;q21). 54 61
16512826 2006
35
MALT1 and BCL10 aberrations in MALT lymphomas and their effect on the expression of BCL10 in the tumour cells. 54 61
16341151 2006
36
Cytogenetic and clinicopathological characterization by fluorescence in situ hybridization on paraffin-embedded tissue sections of twenty-six cases with malignant lymphoma of small intestine. 54 61
16484127 2006
37
Frequency of chromosomal aneuploidies and deletions of the RB and TP53 genes in MALT lymphomas harboring the t(14;18)(q32;q21). 54 61
16364768 2006
38
[Expression of bcl-10 protein in MALT lymphoma]. 54 61
16545185 2005
39
Overexpression of caspase recruitment domain (CARD) membrane-associated guanylate kinase 1 (CARMA1) and CARD9 in primary gastric B-cell lymphoma. 54 61
16177990 2005
40
BCL10 expression in ocular adnexal lymphomas. 54 61
16310461 2005
41
Nuclear expression of BCL10 or nuclear factor kappa B helps predict Helicobacter pylori-independent status of low-grade gastric mucosa-associated lymphoid tissue lymphomas with or without t(11;18)(q21;q21). 54 61
15845895 2005
42
CXCR3-positive B cells found at elevated frequency in the peripheral blood of patients with MALT lymphoma are attracted by MIG and belong to the lymphoma clone. 54 61
15645433 2005
43
Constitutive NF-kappaB activation by the t(11;18)(q21;q21) product in MALT lymphoma is linked to deregulated ubiquitin ligase activity. 54 61
15894263 2005
44
MALT1 and the API2-MALT1 fusion act between CD40 and IKK and confer NF-kappa B-dependent proliferative advantage and resistance against FAS-induced cell death in B cells. 54 61
15598810 2005
45
[The frequency of API2-MALT1 fusion gene variants in MALT lymphoma and its correlation with apoptosis of MALT lymphoma]. 54 61
15696476 2005
46
MALT lymphoma with t(14;18)(q32;q21)/IGH-MALT1 is characterized by strong cytoplasmic MALT1 and BCL10 expression. 54 61
15682443 2005
47
Point mutation of 5' noncoding region of BCL-6 gene in primary gastric lymphomas. 54 61
15609396 2005
48
Anti-apoptotic action of API2-MALT1 fusion protein involved in t(11;18)(q21;q21) MALT lymphoma. 54 61
15711920 2005
49
[Expression of BCL-10 in gastrointestinal mucosa-associated lymphoid tissue lymphoma]. 54 61
15634591 2004
50
Nuclear expression of BCL10 or nuclear factor kappa B predicts Helicobacter pylori-independent status of early-stage, high-grade gastric mucosa-associated lymphoid tissue lymphomas. 54 61
15337797 2004
Sources

Variations for Lymphoma, Mucosa-Associated Lymphoid Type

About this section

ClinVar genetic disease variations for Lymphoma, Mucosa-Associated Lymphoid Type:

6 ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 BCL10 NM_003921.5(BCL10):c.499dup (p.Ser167fs)duplication Pathogenic 6250 rs387906350 1:85733512-85733513 1:85267829-85267830
2 BCL10 NM_003921.5(BCL10):c.163dup (p.Ile55fs)duplication Pathogenic 6251 rs587776630 1:85736483-85736484 1:85270800-85270801
3 BCL10 NM_003921.5(BCL10):c.345del (p.Gly116fs)deletion Pathogenic 6252 rs587776631 1:85736302-85736302 1:85270619-85270619

Cosmic variations for Lymphoma, Mucosa-Associated Lymphoid Type:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM91182202 haematopoietic and lymphoid tissue,thyroid,lymphoid neoplasm,MALT lymphoma c.652-750T>C p.? 10:89013369-89013369 20

Copy number variations for Lymphoma, Mucosa-Associated Lymphoid Type from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 119732 18 16100000 76117153 Gain MALT1 Mucosa-associated lymphoid tissue lymphomas
2 206010 6 135101251 139048099 Loss TNFAIP3 Mucosa-associated lymphoid tissue lymphomas
Sources

Expression for Lymphoma, Mucosa-Associated Lymphoid Type

About this section
Search GEO for disease gene expression data for Lymphoma, Mucosa-Associated Lymphoid Type.
Sources

Pathways for Lymphoma, Mucosa-Associated Lymphoid Type

About this section

Pathways related to Lymphoma, Mucosa-Associated Lymphoid Type according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 13.59 TRAF2 TLR1 S100A8 MALT1 MADCAM1 IRF4
2
Akt Signaling 63
Show member pathways
 13.25 TRAF2 TLR1 CXCR5 CXCL13 CD40 CCR6
3
Cytokine Signaling in Immune system 65
Show member pathways
 13.18 TRAF2 IRF4 DUSP5 CD40 CCND1 BIRC3
4
Allograft rejection 1 36
Show member pathways
 12.68 MADCAM1 CXCR5 CXCL13 CD40 CCND1
5
NF-KappaB Family Pathway 63
Show member pathways
 12.42 TRAF2 TLR1 MALT1 CD40 CARD11 BCL10
6
Immune response NFAT in immune response 22
Show member pathways
 12.39 MALT1 IGH CD40 CARD11 BCL10
7
ICos-ICosL Pathway in T-Helper Cell 63
Show member pathways
 12.18 MALT1 CD40 CARD11 BCL10
8
B cell receptor signaling pathway (KEGG) 1
Show member pathways
 12.16 MALT1 IRF4 CARD11 BCL6 BCL10
9
Apoptosis and Autophagy 4
12.02 TRAF2 MALT1 BIRC3 BCL10
10
Interleukin-4 and 13 signaling 65
11.81 IRF4 CCND1 BCL6
11
TCR signaling in naive CD4+ T cells 1
Show member pathways
 11.78 MALT1 CARD11 BCL10
12
NF-kappaB Signaling 4
11.74 TRAF2 TLR1 MALT1 IRF4 CXCR5 CARD11
13
Small cell lung cancer 36
11.69 TRAF2 CCND1 BIRC3
14
Innate Lymphoid Cell Differentiation Pathways 64
11.59 IRF4 CXCR5 CCR6
15
Apoptosis and survival Anti-apoptotic TNFs/NF-kB/Bcl-2 pathway 22
Show member pathways
 11.52 TRAF2 CD40 BIRC3
16
NF-kappa B signaling pathway 36
11.44 TRAF2 MALT1 CD40 CARD11 BIRC3 BCL10
17
B Cell Development Pathways 64
11.28 CXCR5 CD5 CD40 BCL6
18
CD40/CD40L signaling 1
11.06 TRAF2 CD40 BIRC3
Sources

GO Terms for Lymphoma, Mucosa-Associated Lymphoid Type

About this section

Cellular components related to Lymphoma, Mucosa-Associated Lymphoid Type according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane raft GO:0045121 9.35 TRAF2 TLR1 CARD11 BIRC3 BCL10
2 CD40 receptor complex GO:0035631 9.16 TRAF2 CD40
3 CBM complex GO:0032449 8.8 MALT1 CARD11 BCL10

Biological processes related to Lymphoma, Mucosa-Associated Lymphoid Type according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 10.03 TLR1 MADCAM1 CXCR5 CXCL13 CCR6
2 immune system process GO:0002376 9.99 TLR1 S100A8 IRF4 CD40 BCL6 BCL10
3 inflammatory response GO:0006954 9.95 TLR1 S100A8 CXCL13 CD40 BCL6
4 regulation of immune response GO:0050776 9.92 MADCAM1 CD40 CARD11 BCL6
5 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.83 MALT1 CARD11 BCL10
6 cell chemotaxis GO:0060326 9.81 CXCR5 CXCL13 CCR6
7 chemotaxis GO:0006935 9.8 S100A8 CXCR5 CXCL13 CCR6
8 positive regulation of protein ubiquitination GO:0031398 9.79 MALT1 BIRC3 BCL10
9 chemokine-mediated signaling pathway GO:0070098 9.78 CXCR5 CXCL13 CCR6
10 protein heterooligomerization GO:0051291 9.73 TRAF2 BIRC3 BCL10
11 activation of NF-kappaB-inducing kinase activity GO:0007250 9.65 TRAF2 MALT1
12 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.65 IRF4 CARD11
13 positive regulation of interleukin-2 production GO:0032743 9.64 TRAF2 MALT1
14 response to molecule of bacterial origin GO:0002237 9.63 MALT1 BCL10
15 toll-like receptor signaling pathway GO:0002224 9.63 TLR1 S100A8 BCL10
16 regulation of apoptotic process GO:0042981 9.63 TRAF2 MALT1 CARD11 BIRC3 BCL6 BCL10
17 macrophage activation GO:0042116 9.62 TLR1 FOXP1
18 regulation of inflammatory response GO:0050727 9.62 S100A8 FOXP1 BIRC3 BCL6
19 positive regulation of B cell proliferation GO:0030890 9.61 CD40 CARD11 BCL6
20 negative regulation of B cell apoptotic process GO:0002903 9.6 FOXP1 BCL6
21 positive regulation of T cell cytokine production GO:0002726 9.59 TRAF2 MALT1
22 leukocyte migration involved in inflammatory response GO:0002523 9.58 S100A8 CCR6
23 chronic inflammatory response GO:0002544 9.58 S100A8 CXCL13
24 B cell activation GO:0042113 9.58 MALT1 CXCR5 CD40
25 germinal center formation GO:0002467 9.57 CXCL13 BCL6
26 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.56 TRAF2 CARD11 BIRC3 BCL10
27 regulation of T cell receptor signaling pathway GO:0050856 9.54 MALT1 BCL10
28 positive regulation of T cell activation GO:0050870 9.54 MALT1 CARD11 BCL10
29 response to fungus GO:0009620 9.52 MALT1 BCL10
30 regulation of immunoglobulin secretion GO:0051023 9.48 TRAF2 CD40
31 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.43 TRAF2 MALT1 CD40 CARD11 BIRC3 BCL10
32 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.1 TRAF2 S100A8 MALT1 CD40 CARD11 BCL10

Molecular functions related to Lymphoma, Mucosa-Associated Lymphoid Type according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor activity GO:0038023 9.56 TLR1 CD5 CD40 CCR6
2 CARD domain binding GO:0050700 9.32 CARD11 BCL10
3 kinase activator activity GO:0019209 9.16 MALT1 BCL10
4 protein self-association GO:0043621 9.13 MALT1 FOXP1 BCL10
5 enzyme binding GO:0019899 9.02 TRAF2 KDM4C CD40 CCND1 BCL10
Sources

Sources for Lymphoma, Mucosa-Associated Lymphoid Type

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....